Mizuho raised the firm’s price target on Tandem Diabetes (TNDM) to $18 from $16 and keeps a Neutral rating on the shares.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TNDM:
- Tandem Diabetes Care: Strong Buy Rating Backed by Strategic Growth Initiatives and Attractive Valuation
- Tandem Diabetes price target raised to $55 from $51 at Barclays
- Tandem Diabetes price target raised to $18 from $16 at Baird
- Tandem Diabetes Care Reports Record Third-Quarter Sales
- Tandem Diabetes Care: Strong Q3 Performance and Positive Outlook Justify Buy Rating